Company intelligence / Profile preview

Magstim

Eden Prairie, Minnesota, United Statesmagstim.com ↗

Ownership: Private
Development stage: Commercial

Overview

Magstim’s Horizon 3.0 TMS Therapy System and related neurostimulation devices are FDA-cleared and CE-marked for the treatment of major depressive disorder—including adolescent MDD—anxious depression, and OCD. Their systems are widely used in both clinical practice and research settings globally. Over 16,000 published studies cite the use of their stimulators. Clinical feedback highlights significant improvements in patient outcomes with few adverse effects.

Therapeutic areas: Psychiatry
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Collaborates with leading medical/research institutions worldwide; no specific pharma/biotech partnerships named

Beyond the preview

Go deeper on Magstim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magstim.

Explore the full profile